New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Who is Janssen? We’re people; more than 35,000, working hard to treat, cure, stop and prevent some of the most devastating and complex diseases of our time — from diabetes and HIV, to Alzheimer’s and cancer.
Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolism. We are driven to action by the plight of patients, and we aspire to make a positive impact on their lives. That’s why we never limit the search for new medicines to our own four walls—we’re always looking to work with partners interested in helping us achieve our goals.
We stay focused on the disease areas where we believe we can make the biggest difference — oncology, neuroscience, immunology, infectious diseases & vaccines, and cardiovascular & metabolism. But success for us doesn’t stop in our labs.
The world is our lab, and we wouldn’t be able to achieve our success if it weren’t for our approach to collaboration. We work closely with like-minded people from researchers to governments, healthcare professionals to patient organizations. And we work with them at every stage, from early discovery to market access and patient education. Our experts collaborate with external parties at every stage of our value chain—from early discovery to market access. We seek medical breakthroughs wherever they occur. Whether you’re at a university, a research organization, or another biotech or pharmaceutical company, we want to hear from you.
We are Janssen. We collaborate with the world for the health of everyone in it.
Contact
Janssen-Cilag Kft.
H-1123 Budapest
Nagyenyed u. 8-14.
Tel.: + 36 1 884-2858
Fax.: + 36 1 884-2939
e-mail: janssenpharmahu@its.jnj.com
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
